ASX - By Stock
|
ATX |
Re:
Thoughts on ATX, is it a multi bagger?
|
|
RLGphd
|
25 |
10K |
2 |
15/09/21 |
15/09/21 |
ASX - By Stock
|
25
|
10K
|
2
|
|
ASX - By Stock
|
ATX |
Re:
Ann: Results of Annual General Meeting
|
|
RLGphd
|
11 |
3.2K |
1 |
31/08/21 |
31/08/21 |
ASX - By Stock
|
11
|
3.2K
|
1
|
|
ASX - By Stock
|
ATX |
Re:
Ann: AGM - Chief Executive Officer's Presentatioin
|
|
RLGphd
|
2 |
1.0K |
6 |
27/08/21 |
27/08/21 |
ASX - By Stock
|
2
|
1.0K
|
6
|
|
ASX - By Stock
|
PBH |
Re:
Pointsbet growth
|
|
RLGphd
|
170 |
77K |
0 |
26/08/21 |
26/08/21 |
ASX - By Stock
|
170
|
77K
|
0
|
|
ASX - By Stock
|
PBH |
Re:
just joined pb
|
|
RLGphd
|
64 |
13K |
0 |
16/08/21 |
16/08/21 |
ASX - By Stock
|
64
|
13K
|
0
|
|
ASX - By Stock
|
ATX |
Re:
Thoughts on ATX, is it a multi bagger?
|
|
RLGphd
|
25 |
10K |
7 |
05/08/21 |
05/08/21 |
ASX - By Stock
|
25
|
10K
|
7
|
|
ASX - By Stock
|
ATX |
Re:
Ann: Quarterly Activities and Cashflow Reports and Presentation
|
|
RLGphd
|
12 |
3.4K |
3 |
04/08/21 |
04/08/21 |
ASX - By Stock
|
12
|
3.4K
|
3
|
|
ASX - By Stock
|
ATX |
Re:
Ann: Quarterly Activities and Cashflow Reports and Presentation
|
|
RLGphd
|
12 |
3.4K |
4 |
03/08/21 |
03/08/21 |
ASX - By Stock
|
12
|
3.4K
|
4
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Half Year Report and Update
|
|
RLGphd
|
116 |
35K |
3 |
09/03/21 |
09/03/21 |
ASX - By Stock
|
116
|
35K
|
3
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Half Year Report and Update
|
|
RLGphd
|
116 |
35K |
1 |
09/03/21 |
09/03/21 |
ASX - By Stock
|
116
|
35K
|
1
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Half Year Report and Update
|
|
RLGphd
|
116 |
35K |
1 |
08/03/21 |
08/03/21 |
ASX - By Stock
|
116
|
35K
|
1
|
|
ASX - By Stock
|
PBH |
Re:
PBH Charts
|
|
RLGphd
|
1.0K |
429K |
0 |
05/03/21 |
05/03/21 |
ASX - By Stock
|
1.0K
|
429K
|
0
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Half Year Report and Update
|
|
RLGphd
|
116 |
35K |
2 |
04/03/21 |
04/03/21 |
ASX - By Stock
|
116
|
35K
|
2
|
|
ASX - By Stock
|
IMM |
Re:
Ann: Immutep granted US patent for eftilagimod alpha with a PD-1
|
|
RLGphd
|
39 |
23K |
7 |
02/03/21 |
02/03/21 |
ASX - By Stock
|
39
|
23K
|
7
|
|
Charts
|
ATX |
Re:
Atx chart
|
|
RLGphd
|
7 |
3.1K |
3 |
26/02/21 |
26/02/21 |
Charts
|
7
|
3.1K
|
3
|
|
ASX - By Stock
|
IMM |
Re:
Ann: Half Yearly Report and Accounts
|
|
RLGphd
|
33 |
17K |
2 |
26/02/21 |
26/02/21 |
ASX - By Stock
|
33
|
17K
|
2
|
|
ASX - By Stock
|
IMM |
Re:
Ann: Half Yearly Report and Accounts
|
|
RLGphd
|
33 |
17K |
11 |
24/02/21 |
24/02/21 |
ASX - By Stock
|
33
|
17K
|
11
|
|
ASX - By Stock
|
IMM |
Re:
Ann: Half Yearly Report and Accounts
|
|
RLGphd
|
33 |
17K |
8 |
23/02/21 |
23/02/21 |
ASX - By Stock
|
33
|
17K
|
8
|
|
ASX - By Stock
|
IMM |
Re:
Ann: Half Yearly Report and Accounts
|
|
RLGphd
|
33 |
17K |
8 |
23/02/21 |
23/02/21 |
ASX - By Stock
|
33
|
17K
|
8
|
|
ASX - By Stock
|
ATX |
Re:
Ann: Amplia Initiates Multiple Dose Study of AMP945
|
|
RLGphd
|
7 |
3.2K |
4 |
17/02/21 |
17/02/21 |
ASX - By Stock
|
7
|
3.2K
|
4
|
|
ASX - By Stock
|
ATX |
Re:
Ann: Investor Update - February 2021
|
|
RLGphd
|
9 |
3.1K |
6 |
12/02/21 |
12/02/21 |
ASX - By Stock
|
9
|
3.1K
|
6
|
|
ASX - By Stock
|
ATX |
Re:
Ann: Investor Update - February 2021
|
|
RLGphd
|
9 |
3.1K |
6 |
11/02/21 |
11/02/21 |
ASX - By Stock
|
9
|
3.1K
|
6
|
|
ASX - By Stock
|
PBH |
Re:
PBH Charts
|
|
RLGphd
|
1.0K |
429K |
1 |
04/02/21 |
04/02/21 |
ASX - By Stock
|
1.0K
|
429K
|
1
|
|
ASX - By Stock
|
ATX |
Re:
Ann: Quarterly Activities and Cashflow Reports - Dec 2020 Qtr
|
|
RLGphd
|
10 |
2.6K |
2 |
04/02/21 |
04/02/21 |
ASX - By Stock
|
10
|
2.6K
|
2
|
|
ASX - By Stock
|
IMM |
Re:
Ann: Immutep Corporate Presentation
|
|
RLGphd
|
86 |
37K |
0 |
03/02/21 |
03/02/21 |
ASX - By Stock
|
86
|
37K
|
0
|
|
ASX - By Stock
|
IMM |
Re:
Ann: Immutep Corporate Presentation
|
|
RLGphd
|
86 |
37K |
4 |
03/02/21 |
03/02/21 |
ASX - By Stock
|
86
|
37K
|
4
|
|
ASX - By Stock
|
IMM |
Re:
Ann: Immutep Corporate Presentation
|
|
RLGphd
|
86 |
37K |
0 |
03/02/21 |
03/02/21 |
ASX - By Stock
|
86
|
37K
|
0
|
|
ASX - By Stock
|
IMM |
Re:
Ann: Immutep Corporate Presentation
|
|
RLGphd
|
86 |
37K |
2 |
03/02/21 |
03/02/21 |
ASX - By Stock
|
86
|
37K
|
2
|
|
ASX - By Stock
|
IMM |
Re:
Ann: Immutep Corporate Presentation
|
|
RLGphd
|
86 |
37K |
3 |
02/02/21 |
02/02/21 |
ASX - By Stock
|
86
|
37K
|
3
|
|
ASX - By Stock
|
IMM |
Re:
Ann: Immutep Corporate Presentation
|
|
RLGphd
|
86 |
37K |
0 |
02/02/21 |
02/02/21 |
ASX - By Stock
|
86
|
37K
|
0
|
|
ASX - By Stock
|
IMM |
Re:
Ann: Immutep Corporate Presentation
|
|
RLGphd
|
86 |
37K |
0 |
02/02/21 |
02/02/21 |
ASX - By Stock
|
86
|
37K
|
0
|
|
ASX - By Stock
|
IMM |
Re:
Ann: Immutep Corporate Presentation
|
|
RLGphd
|
86 |
37K |
0 |
02/02/21 |
02/02/21 |
ASX - By Stock
|
86
|
37K
|
0
|
|
ASX - By Stock
|
PBH |
Re:
Ann: Q2 FY21 Investor Presentation
|
|
RLGphd
|
46 |
15K |
1 |
30/01/21 |
30/01/21 |
ASX - By Stock
|
46
|
15K
|
1
|
|
ASX - By Stock
|
IMM |
Re:
Ann: Phase II study for eftilagimod alpha in COVID-19 advances
|
|
RLGphd
|
127 |
64K |
1 |
29/01/21 |
29/01/21 |
ASX - By Stock
|
127
|
64K
|
1
|
|
ASX - By Stock
|
PBH |
Re:
Ann: Q2 FY21 Investor Presentation
|
|
RLGphd
|
46 |
15K |
9 |
29/01/21 |
29/01/21 |
ASX - By Stock
|
46
|
15K
|
9
|
|
ASX - By Stock
|
PBH |
Re:
Ann: Q2 FY21 Investor Presentation
|
|
RLGphd
|
46 |
15K |
1 |
29/01/21 |
29/01/21 |
ASX - By Stock
|
46
|
15K
|
1
|
|
ASX - By Stock
|
PBH |
Re:
Media Update
|
|
RLGphd
|
1.4K |
569K |
0 |
29/01/21 |
29/01/21 |
ASX - By Stock
|
1.4K
|
569K
|
0
|
|
ASX - By Stock
|
PBH |
Re:
Media Update
|
|
RLGphd
|
1.4K |
569K |
0 |
28/01/21 |
28/01/21 |
ASX - By Stock
|
1.4K
|
569K
|
0
|
|
ASX - By Stock
|
PBH |
Re:
PBH Charts
|
|
RLGphd
|
1.0K |
429K |
0 |
28/01/21 |
28/01/21 |
ASX - By Stock
|
1.0K
|
429K
|
0
|
|
ASX - By Stock
|
IMM |
Re:
Ann: Phase II study for eftilagimod alpha in COVID-19 advances
|
|
RLGphd
|
127 |
64K |
3 |
28/01/21 |
28/01/21 |
ASX - By Stock
|
127
|
64K
|
3
|
|
ASX - By Stock
|
IMM |
Re:
Ann: Phase II study for eftilagimod alpha in COVID-19 advances
|
|
RLGphd
|
127 |
64K |
0 |
28/01/21 |
28/01/21 |
ASX - By Stock
|
127
|
64K
|
0
|
|
ASX - By Stock
|
PBH |
Re:
PBH Charts
|
|
RLGphd
|
1.0K |
429K |
0 |
28/01/21 |
28/01/21 |
ASX - By Stock
|
1.0K
|
429K
|
0
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Dimerix Plans for Next Study in Diabetic Kidney Disease
|
|
RLGphd
|
169 |
40K |
0 |
28/01/21 |
28/01/21 |
ASX - By Stock
|
169
|
40K
|
0
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Dimerix Plans for Next Study in Diabetic Kidney Disease
|
|
RLGphd
|
169 |
40K |
0 |
28/01/21 |
28/01/21 |
ASX - By Stock
|
169
|
40K
|
0
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Dimerix Plans for Next Study in Diabetic Kidney Disease
|
|
RLGphd
|
169 |
40K |
1 |
28/01/21 |
28/01/21 |
ASX - By Stock
|
169
|
40K
|
1
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Dimerix Plans for Next Study in Diabetic Kidney Disease
|
|
RLGphd
|
169 |
40K |
1 |
28/01/21 |
28/01/21 |
ASX - By Stock
|
169
|
40K
|
1
|
|
ASX - By Stock
|
IMM |
Re:
Ann: Phase II study for eftilagimod alpha in COVID-19 advances
|
|
RLGphd
|
127 |
64K |
3 |
27/01/21 |
27/01/21 |
ASX - By Stock
|
127
|
64K
|
3
|
|
ASX - By Stock
|
PBH |
Re:
Ann: PointsBet Signs Shaquille O'Neal As AU Ambassador
|
|
RLGphd
|
48 |
14K |
1 |
25/01/21 |
25/01/21 |
ASX - By Stock
|
48
|
14K
|
1
|
|
ASX - By Stock
|
PBH |
Re:
PBH 2021
|
|
RLGphd
|
114 |
47K |
0 |
24/01/21 |
24/01/21 |
ASX - By Stock
|
114
|
47K
|
0
|
|
ASX - By Stock
|
PBH |
Re:
PBH 2021
|
|
RLGphd
|
114 |
47K |
20 |
22/01/21 |
22/01/21 |
ASX - By Stock
|
114
|
47K
|
20
|
|